Bryan Ball - 11 Jul 2022 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC.

Reporting relationship: Chief Qual. Officer & SVP Ops.
Issuer ticker: N/A
Reported as of: 11 Jul 2022
Net transaction value: -$6,353
SEC form: 4
Accepted by SEC: 13 Jul 2022, 16:01:33 UTC
Prior SEC filing: 13 Apr 2022
Next SEC filing: 26 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Rocco Venezia, as attorney-in-fact

Key filing fact

Bryan Ball filed Form 4 for INTERCEPT PHARMACEUTICALS, INC. on 13 Jul 2022.

Key facts

This page summarizes Bryan Ball's Form 4 filing for INTERCEPT PHARMACEUTICALS, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Jul 2022, 16:01.

Change

Previous filing in this sequence was filed on 13 Apr 2022.
Current net transaction value: -$6,353.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICPT transaction

Common Stock

Tax liability

Transaction value: $6,353
Shares: -436
Change %: -1.7%
Price: $14.57
Shares after: 25,178
Date: 11 Jul 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.